QuidelOrtho Showcases Leadership in Transfusion Medicine at AABB 2025
QuidelOrtho (Nasdaq: QDEL) will highlight its transfusion medicine portfolio at the AABB 2025 Annual Meeting on Oct 16–17, 2025, following the FDA approval of the MTS™ DAT Card.
The MTS DAT Card completes the company's gel-based direct antiglobulin testing solution and, when paired with the ORTHO VISION™ Platform, offers column agglutination technology with software features like reflex testing and as-needed quality control to speed and standardize transfusion decisions.
Planned activities include education sessions on Rh(D) antigen and DARA interference, poster data on IgG/C3 detection and instrumentation reliability, and product demos of ORTHO VISION Max Swift, ORTHO VISION Swift (noting 98% uptime), and ORTHO CONNECT lab management software.
QuidelOrtho (Nasdaq: QDEL) evidenzierà il suo portafoglio di medicina della trasfusione all'AABB 2025 Annual Meeting il 16–17 ottobre 2025, a seguito dell'approvazione FDA del MTS™ DAT Card.
La MTS DAT Card completa la soluzione di test antiglobulina diretta basata su gel dell'azienda e, se abbinata alla ORTHO VISION™ Platform, offre una tecnologia di agglutinazione a colonna con funzioni software come test di riflesso e controllo qualità su richiesta per accelerare e standardizzare le decisioni di trasfusione.
Le attività previste includono sessioni educative sull'antigene Rh(D) e sull'interferenza DARA, dati poster su rilevamento IgG/C3 e affidabilità degli strumenti, e dimostrazioni di prodotto di ORTHO VISION Max Swift, ORTHO VISION Swift (notando un uptime del 98%) e il software di gestione del laboratorio ORTHO CONNECT.
QuidelOrtho (Nasdaq: QDEL) destacará su cartera de medicina de transfusión en la Reunión Anual AABB 2025 los días 16-17 de oct de 2025, tras la aprobación de la FDA del MTS™ DAT Card.
La MTS DAT Card completa la solución de pruebas de antiglobulina directa en gel de la empresa y, cuando se combina con la Plataforma ORTHO VISION™, ofrece tecnología de aglutinación en columna con funciones de software como pruebas de reflejo y control de calidad bajo demanda para acelerar y estandarizar las decisiones de transfusión.
Las actividades previstas incluyen sesiones de educación sobre el antígeno Rh(D) e interferencia de DARA, datos de póster sobre detección de IgG/C3 y fiabilidad de los instrumentos, y demostraciones de producto de ORTHO VISION Max Swift, ORTHO VISION Swift (con un uptime del 98%), y el software de gestión de laboratorio ORTHO CONNECT.
퀴델오르소(QuideOrtho) (나스닥: QDEL)은 2025년 10월 16–17일 AABB 연례 회의에서 자사 수혈 의학 포트폴리오를 강조할 예정이며, MTS™ DAT Card의 FDA 승인을 계기로 이루어집니다.
MTS DAT Card는 회사의 겔 기반 직접 항글로불린 검사 솔루션을 완성하고, ORTHO VISION™ Platform과 결합될 때 소프트웨어 기능으로 반사 검사 및 필요시 품질 관리와 함께 열판 응집 기술을 제공해 수혈 결정의 속도와 표준화를 돕습니다.
계획된 활동으로는 Rh(D) 항원 및 DARA 간섭에 대한 교육 세션, IgG/C3 탐지 및 기기 신뢰성에 대한 포스터 데이터, 그리고 ORTHO VISION Max Swift, ORTHO VISION Swift(가동시간 98% 주목) 및 ORTHO CONNECT 실험실 관리 소프트웨어의 시연이 포함됩니다.
QuidelOrtho ( Nasdaq : QDEL ) mettra en lumière son portefeuille de médecine de la transfusion lors de la Reunion annuelle AABB 2025 les 16 et 17 octobre 2025, à la suite de l'approbation de la FDA du MTS™ DAT Card.
Le MTS DAT Card complète la solution de test antiglobuline directe sur gel de l'entreprise et, associée à la Plateforme ORTHO VISION™, offre une technologie d'agglutination en colonne avec des fonctionnalités logicielles telles que les tests réflexes et le contrôle qualité sur demande pour accélérer et standardiser les décisions de transfusion.
Les activités prévues incluent des sessions d'éducation sur l'antigène Rh(D) et l'interférence DARA, des données de posters sur la détection IgG/C3 et la fiabilité des instruments, et des démonstrations produit de ORTHO VISION Max Swift, ORTHO VISION Swift (avec un taux de disponibilité de 98%), et du logiciel de gestion de laboratoire ORTHO CONNECT.
QuidelOrtho (Nasdaq: QDEL) wird sein Transfusionsmedizin-Portfolio auf der AABB 2025 Jahresversammlung am 16.–17. Oktober 2025 hervorheben, nach der FDA-Zulassung des MTS™ DAT Card.
Die MTS DAT Card vervollständigt die gel-basierte direkte Antiglobulin-Testlösung des Unternehmens und bietet, in Kombination mit der ORTHO VISION™ Platform, eine Spaltagglutinationstechnologie mit Software-Funktionen wie Reflex-Testing und bedarfsgesteuerter Qualitätskontrolle, um Transfusionsentscheidungen zu beschleunigen und zu standardisieren.
Geplante Aktivitäten umfassen Bildungssitzungen zu Rh(D)-Antigen und DARA-Interferenz, Poster-Daten zur IgG/C3-Erkennung und Instrumentenverlässigkeit sowie Produktdemos von ORTHO VISION Max Swift, ORTHO VISION Swift (mit 98%-Verfügbarkeit) und der Laborverwaltungssoftware ORTHO CONNECT.
QuidelOrtho (ناسداك: QDEL) سيبرز محفظته في طب نقل الدم في اجتماع AABB السنوي 2025 في 16-17 أكتوبر 2025، وذلك بعد اعتماد FDA لـ MTS™ DAT Card.
يكمل MTS DAT Card حلاً لاختبار الأجسام المضادة المباشرة المعتمدة على الهلام، وعند اقترانه بـ ORTHO VISION™ Platform، يوفر تكنولوجيا التجمّع العمودي مع ميزات برمجية مثل الاختبار الانعكاسي والرقابة الجودة عند الطلب لتسريع قرارات النقل الدموي وتوحيدها.
تشمل الأنشطة المخطط لها جلسات تعليمية حول مستضد Rh(D) وتداخل DARA، وبيانات الملصقات حول اكتشاف IgG/C3 وموثوقية الأجهزة، وعروض منتجات ORTHO VISION Max Swift و ORTHO VISION Swift (مع معدل جاهزية 98٪) وبرنامج إدارة المختبرات ORTHO CONNECT.
QuidelOrtho (纳斯达克股票代码：QDEL) 将在 AABB 2025 年年会于 2025 年 10 月 16–17 日重点介绍其输血医学产品组合，此举是在 FDA 批准 MTS™ DAT Card之后。
MTS DAT Card 完成了公司基于凝胶的直接抗人球蛋白测试解决方案，与 ORTHO VISION™ Platform 配对时，提供柱状凝集技术以及如反射测试和按需质量控制等软件功能，以加速并标准化输血决策。
计划的活动包括关于 Rh(D) 抗原及 DARA 干扰的教育会、关于 IgG/C3 检测及仪器可靠性的海报数据，以及 ORTHO VISION Max Swift、ORTHO VISION Swift（注意 98% 的正常运行时间）和 ORTHO CONNECT 实验室管理软件的产品演示。
- FDA approval of MTS DAT Card for direct antiglobulin testing
- MTS DAT Card completes gel-based solution when paired with ORTHO VISION
- ORTHO VISION Swift reports 98% uptime, supporting lab reliability
- None.
Insights
FDA approval of the MTS™ DAT Card plus ORTHO VISION platform strengthens QuidelOrtho's lab automation and DAT offerings for transfusion decisions.
QuidelOrtho pairs a newly FDA-approved MTS™ DAT Card with its ORTHO VISION™ platform to deliver a gel-based direct antiglobulin testing workflow. The combination adds a gel-card DAT into an automated system that includes reflex testing and as-needed quality control, which can shorten time-to-result and standardize testing in high-volume transfusion laboratories.
The near-term impact depends on lab adoption, instrument connectivity, and procurement cycles. Performance claims such as
Watch for customer validation studies, rollout cadence for the MTS DAT Card across ORTHO VISION instruments, and published comparative performance metrics at AABB 2025 and in subsequent months. Expect procurement and validation activity to unfold over the next several quarters as labs evaluate integration and workflow gains.
FDA-approved MTS™ DAT Card and advanced ORTHO VISION™ Platform highlight the company's continued leadership in transfusion medicine
The MTS DAT Card completes QuidelOrtho's gel-based solution for direct antiglobulin testing. When paired with the ORTHO VISION™ Platform, it combines proven column agglutination technology with advanced software capabilities – including reflex testing and as-needed quality control – to help laboratories deliver faster, more reliable results for patients who depend on timely transfusion decisions.
"The AABB Annual Meeting brings together the world's foremost leaders in blood and biotherapies," said Michelle Mullens, Global Product Manager, Portfolio Solutions Transfusion Medicine, at QuidelOrtho. "Our participation reinforces our dedication to driving innovation that advances laboratory performance and enhances efficiency, helping to improve patient outcomes worldwide."
Featured education sessions
-
Sunday, 10:00–10:30 a.m. PT
Missing Formula: The Challenging World of Rh(D) Antigen
Sue T. Johnson, MSTM, MLS(ASCP)SBBCM
An in-depth look at the complexities of Rh(D) antigen identification and its implications for transfusion safety. -
Monday, 11:40 a.m.–12:10 p.m. PT
Identifying the Imposter: How ID-MTS Gel Test Typing Can Help Blood Banks with DARA Patients
Lehang Dingh, MLS(ASCP)SBBCM
Explore how gel testing can help distinguish true antibodies from drug interference in patients treated with daratumumab. -
Monday, 1:45–2:15 p.m. PT
Type & Seek: Solution to the Patient Puzzle
Shane Grimsley, DipRCPath, FBBTS, Senior Clinical Scientist, IBGRL
Learn strategies for resolving complex serological cases using advanced immunohematology techniques.
Poster presentations
- Evaluation of a Gel Card Being Designed for the Detection of IgG and C3
- Reliability of Instrumentation for Immunohematology Testing in the Transfusion Medicine Laboratory
These posters offer insights into performance and reliability metrics that support confident decision-making in the lab.
Product demonstrations
-
ORTHO VISION™ Max Swift Analyzer
Max Capacity. Max Efficiency.
Built for high-throughput labs, the ORTHO VISION Max Swift Analyzer delivers speed, reliability and walkaway automation with expanded capacity for samples and reagents. -
ORTHO VISION™ Swift Analyzer
Automation. Precision. Confidence.
Simplifies transfusion testing with98% uptime and consistent, high-quality results powered by ID-MTS™ Gel Test technology. -
ORTHO CONNECT™ Lab Management Software
Centralized Workflow Automation.
Supports lab networks with middleware that streamlines operations, addresses staffing challenges and helps meet compliance demands.
Learn more and register
Explore the full agenda and secure your spot: https://cvent.me/bA4rgD?utm_source=webmax&utm_campaign=aabb25&utm_medium=media&utm_term=register-now&RefId=media
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to lab, clinic to hospital. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
|
Investor Contact: Juliet Cunningham Vice President, Investor Relations IR@QuidelOrtho.com |
Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications Media@QuidelOrtho.com |
View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-showcases-leadership-in-transfusion-medicine-at-aabb-2025-302587015.html
SOURCE QuidelOrtho Corporation
FAQ
What did QuidelOrtho (QDEL) announce at AABB 2025 on Oct 16–17, 2025?
How does the FDA-approved MTS DAT Card affect QuidelOrtho's product offering (QDEL)?
Which ORTHO VISION systems will QuidelOrtho demo at AABB 2025 and what is their benefit?
What clinical topics did QuidelOrtho present at AABB 2025 relevant to transfusion safety (QDEL)?
Will QuidelOrtho (QDEL) present data supporting MTS or instrumentation reliability at AABB 2025?
